In summary, our data support the notion that increased pretreatment tumor levels of caspase-8 and CDK9 predict superior clinical responses in cervical cancer patients treated with definitive CRT plus BT, while higher levels of pCDK9 detection are predictive of an impaired clinical response. This evidence concerns the gene CASP8 and neoplasm.